AU2020339557B2 - Composition used for combating metabolic diseases and uses of composition - Google Patents

Composition used for combating metabolic diseases and uses of composition

Info

Publication number
AU2020339557B2
AU2020339557B2 AU2020339557A AU2020339557A AU2020339557B2 AU 2020339557 B2 AU2020339557 B2 AU 2020339557B2 AU 2020339557 A AU2020339557 A AU 2020339557A AU 2020339557 A AU2020339557 A AU 2020339557A AU 2020339557 B2 AU2020339557 B2 AU 2020339557B2
Authority
AU
Australia
Prior art keywords
rule
pct
therapeutic agent
nash
control
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020339557A
Other languages
English (en)
Other versions
AU2020339557A1 (en
Inventor
Shi Lin MA
Shyh Chang NG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute of Zoology
Original Assignee
Institute of Zoology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute of Zoology filed Critical Institute of Zoology
Publication of AU2020339557A1 publication Critical patent/AU2020339557A1/en
Application granted granted Critical
Publication of AU2020339557B2 publication Critical patent/AU2020339557B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2020339557A 2019-08-30 2020-08-28 Composition used for combating metabolic diseases and uses of composition Active AU2020339557B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2019103677 2019-08-30
CNPCT/CN2019/103677 2019-08-30
PCT/CN2020/112143 WO2021037212A1 (zh) 2019-08-30 2020-08-28 用于对抗代谢疾病的组合物及其用途

Publications (2)

Publication Number Publication Date
AU2020339557A1 AU2020339557A1 (en) 2022-03-24
AU2020339557B2 true AU2020339557B2 (en) 2026-05-07

Family

ID=74683374

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020339557A Active AU2020339557B2 (en) 2019-08-30 2020-08-28 Composition used for combating metabolic diseases and uses of composition

Country Status (9)

Country Link
US (1) US20220323408A1 (enExample)
EP (1) EP4023225B1 (enExample)
JP (1) JP7645244B2 (enExample)
KR (1) KR20220054351A (enExample)
CN (1) CN114364385B (enExample)
AU (1) AU2020339557B2 (enExample)
CA (1) CA3152868A1 (enExample)
IL (1) IL290927A (enExample)
WO (1) WO2021037212A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4069209A4 (en) * 2019-12-05 2024-04-10 Flagship Pioneering Innovations V, Inc. ACYLATED ACTIVE AGENTS AND METHODS OF USE THEREOF FOR THE TREATMENT OF METABOLIC DISEASES AND NON-ALCOHOLIC FATTY LIVER DISEASE
CN116583274A (zh) * 2020-12-14 2023-08-11 医学文库有限责任公司 用于治疗和预防微生物感染性疾病和相关炎性障碍的方法和药物组合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5127093B1 (enExample) 1970-11-11 1976-08-10
DE3574867D1 (de) 1984-04-02 1990-01-25 Cornell Res Foundation Inc Aminokarnitine.
HUT65327A (en) 1992-06-11 1994-05-02 Sandoz Ag Process for producing phosphinyloxy-propyl-ammonium inner sact derwatives ang pharmateutical preparations containing them
IT1299266B1 (it) 1998-05-15 2000-02-29 Sigma Tau Ind Farmaceuti Inibitori reversibili della carnitina palmitoil trasferasi
CN101702884A (zh) * 2007-03-09 2010-05-05 西姆科皮亚公司 用于治疗高血糖症及相关病症的脂肪酸氧化抑制剂
US20110275649A1 (en) * 2010-05-05 2011-11-10 Palmetto Pharmaceuticals Llc Combination therapy for the prevention of statin induced diabetes
US20130316029A1 (en) * 2010-12-21 2013-11-28 Nestec S.A. Methods and compositions suitable for managing blood glucose in animals

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LU YU; LI HAITAO; YANG YOUMING: "Clinical Study of Trimetazidine Combined with Aspirin on Treatment of Unstable Angina: Report of 82 Cases", CHINESE JOURNAL OF TRAUMA AND DISABILITY MEDICINE, CHINESE REHABILITATION MEDICINE ASSOCIATION, CN, vol. 22, no. 10, 31 December 2014 (2014-12-31), CN, pages 143 - 144, XP009526503, ISSN: 1673-6567, DOI: 10.13214/j.cnki.cjotadm.2014.10.127 *

Also Published As

Publication number Publication date
IL290927A (en) 2022-04-01
EP4023225B1 (en) 2026-01-28
EP4023225C0 (en) 2026-01-28
CN114364385A (zh) 2022-04-15
CN114364385B (zh) 2025-05-27
JP2022546987A (ja) 2022-11-10
WO2021037212A9 (zh) 2022-03-24
AU2020339557A1 (en) 2022-03-24
EP4023225A1 (en) 2022-07-06
JP7645244B2 (ja) 2025-03-13
EP4023225A4 (en) 2023-08-30
CA3152868A1 (en) 2021-03-04
KR20220054351A (ko) 2022-05-02
US20220323408A1 (en) 2022-10-13
WO2021037212A1 (zh) 2021-03-04

Similar Documents

Publication Publication Date Title
Shen et al. Beneficial effects of combination therapy of phloretin and metformin in streptozotocin-induced diabetic rats and improved insulin sensitivity in vitro
JP6387010B2 (ja) 血中グルコースレベルを制御することによる糖尿病及び関連容態の処置のための組成物、方法及び使用
Yang et al. Resveratrol ameliorates hepatic metaflammation and inhibits NLRP3 inflammasome activation
Choi et al. Melatonin attenuates carbon tetrachloride–induced liver fibrosis via inhibition of necroptosis
Li et al. Rosmarinic acid protects mice from lipopolysaccharide/d-galactosamine-induced acute liver injury by inhibiting MAPKs/NF-κB and activating Nrf2/HO-1 signaling pathways
US10617689B2 (en) Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level
Chen et al. Effects of combining linagliptin treatment with BI-38335, a novel SGLT2 inhibitor, on pancreatic islet function and inflammation in db/db mice
Kim et al. Globular adiponectin protects rat hepatocytes against acetaminophen-induced cell death via modulation of the inflammasome activation and ER stress: critical role of autophagy induction
KR20190108141A (ko) 조합 치료요법용 약학 조성물
KR20190117632A (ko) Ppar 효현제와 fxr 효현제의 병용
Ouyang et al. A natural compound jaceosidin ameliorates endoplasmic reticulum stress and insulin resistance via upregulation of SERCA2b
Zhang et al. Involvement of glucose-regulated protein 78 and spliced X-box binding protein 1 in the protective effect of gliclazide in diabetic nephropathy
EP4023225B1 (en) Combinations of a salicylate and trimetazidine for use in the treatment of metabolic diseases
US20080279843A1 (en) Method For Improving Insulin Sensitivity By Administering an Inhibitor of Antitrypsin
Ren et al. A novel PPARα/γ agonist, propane-2-sulfonic acid octadec-9-enyl-amide, ameliorates insulin resistance and gluconeogenesis in vivo and vitro
KR102633249B1 (ko) 조합 치료를 위한 약학 조성물
Hsu et al. The beneficial effects of tetracosanol on insulin-resistance by insulin receptor kinase sensibilisation
RU2827553C1 (ru) Композиция, используемая для борьбы с метаболическими заболеваниями, и применения композиции
Shen et al. Tongxinluo preserves the renal function in diabetic kidney disease via protecting the HK-2 cells from the patterns of programmed cell death
KR101642042B1 (ko) 티아졸리딘디온의 p35 및 p25 활성 변화에 대한 용도
HK40071125A (en) Composition used for combating metabolic diseases and uses of composition
CA3077036A1 (en) Compositions and methods for treating septic cardiomyopathy
JP5634985B2 (ja) インスリン抵抗性およびβ−細胞機能障害に関連する疾患を治療するためのリメポリドを含む医薬組成物
Tajima et al. Combination of TS-021 with metformin improves hyperglycemia and synergistically increases pancreatic β-cell mass in a mouse model of type 2 diabetes
Fang et al. Intervention effects of compound Houttuyniae Herba to diabetic renal damage based on SOCS-JAK/STAT negative feedback regulation